[Skip to Navigation]
July 1989

Safety of Intrathecal Steroids in Multiple Sclerosis-Reply

Author Affiliations

48 Omega Dr Omega Professional Center Newark, DE 19713

Arch Neurol. 1989;46(7):718-719. doi:10.1001/archneur.1989.00520430012004

In Reply.  —Between 1960 and 1962, six studies performed on more than 5000 patients reported sanguine results from the intrathecal use of methylprednisolone acetate (Depo-Medrol).1 Numerous regimens were tried. Sehgal and Gardner2 advocated it after treating 3000 patients for "failed disk syndrome," arachnoiditis, cluster headache, pseudotumor cerebri, plexitis, Guillain-Barré syndrome, and multiple sclerosis. Only minor side effects were mentioned and the steroid was reported uniformly helpful. These authors mentioned six negative autopsy reports in a two-sentence description, and no details were given. Boines3 simultaneously tested the compound on more than 2000 patients with multiple sclerosis and reported improvement from 75% to 90%, regardless of the stage of the disease; spasticity was stated to have been relieved, even in patients with chronic disease.Between 1964 and 1969, three authors4-6 attempted to treat spasticity in multiple sclerosis and other diseases by a variety of regimens, and their results were poor.

Add or change institution